Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa

BMC Infectious Diseases

Volumn 7, Issue , 2007, Pages

  Lawn, Stephen D ^a,b   Myer, Landon ^a,c   Bangani, Nonzwakazi ^a   Vogt, Monica ^a   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; COTRIMOXAZOLE; DAPSONE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SOUTH AFRICA; SURVIVAL RATE; BLOOD; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, CELL SURFACE; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 34250185656     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-7-41     Document Type: Article

References (35)

1. UNAIDS/WHO AIDS epidemic update: December 2005.
2. UNAIDS WHO Progress on global access to HIV antiretroviral therapy. A report by "3 by 5" and beyond. March 2006
3. WHO/UNAIDS Press release: HIV infection rates decreasing in several countries but global number of people living with HIV continues to rise. November, 2005. http://www.who.int/hiv/epiupdate2005/en/print.html
4. Stringer JS Zulu I Levy J Stringer EM Mwango A Chi BH Mtonga V Reid S Cantrell RA Bulterys M Saag MS Marlink RG Mwinga A Ellerbrock TV Sinkala M Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: Feasibility and early outcomes JAMA 2006 296 782-793 10.1001/ jama.296.7.782 16905784
5. Harries AD Schouten EJ Libamba E Scaling up antiretroviral treatment in resource-poor settings Lancet 2006 367 1870-1872 10.1016/ S0140-6736(06)68809-0 16753490
6. Braitstein P Brinkhof MW Dabis F Schechter M Boulle A Miotti P Wood R Laurent C Sprinz E Seyler C Bangsberg DR Balestre E Sterne JA May M Egger M Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: Comparison between low-income and high-income countries Lancet 2006 367 817-824 10.1016/S0140-6736(06)68337-2 16530575
7. Lawn SD Myer L Orrell C Bekker LG Wood R Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design AIDS 2005 19 2141-2148 16284464
8. Weidle PJ Malamba S Mwebaze R Sozi C Rukundo G Downing R Hanson D Ochola D Mugyenyi P Mermin J Samb B Lackritz E Assessment of a pilot antiretroviral drug therapy programme in Uganda: Patients' response, survival, and drug resistance Lancet 2002 360 34-40 10.1016/ S0140-6736(02)09330-3 12114039
9. Zachariah R Fitzgerald M Massaquoi M Pasulani O Arnould L Makombe S Harries AD Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi AIDS 2006 20 2355-2360 10.1097/QAD.0b013e32801086b0 17117022
10. Etard JF Ndiaye I Thierry-Mieg M Gueye NF Gueye PM Laniece I Dieng AB Diouf A Laurent C Mboup S Sow PS Delaporte E Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: A 7-year cohort study AIDS 2006 20 1181-1189 10.1097/ 01.aids.0000226959.87471.01 16691070
11. Lawn SD Myer L Harling G Orrell C Bekker LG Wood R Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: Implications for program evaluation Clin Infect Dis 2006 43 770-776 10.1086/507095 16912954
12. Lawn SD Wood R How can earlier entry of patients into antiretroviral programs in low-income countries be promoted? Clin Infect Dis 2006 42 431-432 10.1086/499527 16392093
13. Ullum H Lepri AC Katzenstein TL Phillips AN Skinhoj P Gerstoft J Pedersen BK Prognostic value of single measurements of beta-2-microglobulin, immunoglobulin A in HIV disease after controlling for CD4 lymphocyte counts and plasma HIV RNA levels Scand J Infect Dis 2000 32 371-376 10.1080/003655400750044935 10959644
14. Sidenius N Sier CF Ullum H Pedersen BK Lepri AC Blasi F Eugen-Olsen J Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection Blood 2000 96 4091-4095 11110678
15. Ostrowski SR Piironen T Hoyer-Hansen G Gerstoft J Pedersen BK Ullum H High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients J Acquir Immune Defic Syndr 2005 39 23-31 10.1097/01.qai.0000157950.02076.a6 15851910
16. Ostrowski SR Katzenstein TL Piironen T Gerstoft J Pedersen BK Ullum H Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients J Acquir Immune Defic Syndr 2004 35 337-342 10.1097/00126334-200404010-00002 15097149
17. Sier CF Sidenius N Mariani A Aletti G Agape V Ferrari A Casetta G Stephens RW Brunner N Blasi F Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance Lab Invest 1999 79 717-722 10378514
18. Lawn SD Myer L Bekker LG Wood R Early mortality in patients with HIV-associated tuberculosis in Africa: Implications for time to initiation of treatment.Programme and absracts of the 13th Conference on Retroviruses and Opportunistic Infections (CROI).Los Angeles, USA.February 2007.Abstract #0-126
19. Lawn SD Bekker LG Myer L Orrell C Wood R Cryptococcocal immune reconstitution disease: A major cause of early mortality in a South African antiretroviral programme AIDS 2005 19 2050-2052 16260920
20. Bekker LG Myer L Orrell C Lawn S Wood R Rapid scale-up of a community-based HIV treatment service: Programme performance over 3 consecutive years in Guguletu, South Africa S Afr Med J 2006 96 315-320 16670804
21. Lawn SD Myer L Bekker LG Wood R Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: Impact on treatment outcomes and implications for tuberculosis control AIDS 2006 20 1605-1612 16868441
22. Lawn SD Myer L Bekker LG Wood R CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa BMC Infect Dis 2006 6 59 1435908 16551345 10.1186/1471-2334-6-59
23. Organisation. WH Scaling up Antiretroviral Therapy in Resource-limited Settings: Guidelines for a Public Health Approach; Executive Summary. Geneva: World Health Organisation 2002. AccesHed 15.04.05: http//www.who.int/hiv/pub/prev-care/en/WHO_ARV_Guidelines.pdf
24. Lawn SD Myer L Bekker LG Wood R Tuberculosis-associated immune reconstitution disease: Incidence, risk factors and impact in an antiretroviral treatment service in South Africa AIDS 2007 21 335-341 17255740
25. Bamber D The area above the above the ordinal dominance graph and the area below the receiver operating characteristic curve graph. Journal of Mathematical Psychology 1975 387-415 10.1016/0022-2496(75)90001-2
26. Ossowski L guirre-Ghiso JA Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth Curr Opin Cell Biol 2000 12 613-620 10.1016/S0955-0674(00)00140-X 10978898
27. Preissner KT Kanse SM May AE Urokinase receptor: A molecular organizer in cellular communication Curr Opin Cell Biol 2000 12 621-628 10.1016/ S0955-0674(00)00141-1 10978899
28. Eugen-Olsen J Gustafson P Sidenius N Fischer TK Parner J Aaby P Gomes VF Lisse I The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: A community study from Guinea-Bissau Int J Tuberc Lung Dis 2002 6 686-692 12150480
29. Slot O Brunner N Locht H Oxholm P Stephens RW Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: Increased concentrations in rheumatoid arthritis Ann Rheum Dis 1999 58 488-492 1752924 10419867
30. Florquin S van den Berg JG Olszyna DP Claessen N Opal SM Weening JJ van Der PT Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia Kidney Int 2001 59 2054-2061 11380806
31. Lawn SD Butera ST Folks TM Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection Clin Microbiol Rev 2001 14 753-77, table 89002 11585784 10.1128/CMR.14.4.753-777.2001
32. Ferradini L Jeannin A Pinoges L Izopet J Odhiambo D Mankhambo L Karungi G Szumilin E Balandine S Fedida G Carrieri MP Spire B Ford N Tassie JM Guerin PJ Brasher C Scaling up of highly active antiretroviral therapy in a rural district of Malawi: An effectiveness assessment Lancet 2006 367 1335-1342 10.1016/S0140-6736(06)68580-2 16631912
33. Phillips A Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era AIDS 2004 18 51-58 10.1097/ 00002030-200401020-00006 15090829
34. Badri M Lawn SD Wood R Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: A longitudinal study Lancet 2006 368 1254-1259 10.1016/ S0140-6736(06)69117-4 17027731
35. Cozzi Lepri A Katzenstein TL Ullum H Phillips AN Skinhoj P Gerstoft J Pedersen BK The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection AIDS 1998 12 1639-1643 10.1097/00002030-199813000-00011 9764783